Dianthus Therapeutics Q1 2025 Update
Ticker: DNTH · Form: 10-Q · Filed: May 12, 2025 · CIK: 1690585
| Field | Detail |
|---|---|
| Company | Dianthus Therapeutics, INC. /De/ (DNTH) |
| Form Type | 10-Q |
| Filed Date | May 12, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, quarterly-report, pharmaceuticals
TL;DR
Dianthus Therapeutics (DNTH) filed its Q1 2025 10-Q, showing operational status and financial details.
AI Summary
Dianthus Therapeutics, Inc. reported its first quarter 2025 results for the period ending March 31, 2025. The company's former name was Magenta Therapeutics, Inc., with a name change effective November 21, 2016. Dianthus Therapeutics is involved in the pharmaceutical preparations industry, with its principal executive offices located at 7 Times Square, New York, NY.
Why It Matters
This filing provides insight into the financial health and operational status of Dianthus Therapeutics, Inc. as of the first quarter of 2025.
Risk Assessment
Risk Level: low — The filing is a standard quarterly report and does not contain immediate, high-impact news.
Key Numbers
- Q1 2025 — Reporting Period (Period covered by the 10-Q filing)
- March 31, 2025 — As of Date (Date to which financial information pertains)
Key Players & Entities
- Dianthus Therapeutics, Inc. (company) — Filer
- Magenta Therapeutics, Inc. (company) — Former company name
- 20250331 (date) — Reporting period end date
- 20250512 (date) — Filing date
- 7 Times Square, 43rd Floor, New York, NY 10036 (location) — Business and mailing address
FAQ
What was Dianthus Therapeutics' former company name?
Dianthus Therapeutics, Inc.'s former company name was Magenta Therapeutics, Inc.
When was the name change from Magenta Therapeutics, Inc. to Dianthus Therapeutics, Inc. effective?
The date of the name change was November 21, 2016.
What is the primary industry classification for Dianthus Therapeutics, Inc.?
The Standard Industrial Classification for Dianthus Therapeutics, Inc. is Pharmaceutical Preparations [2834].
Where are Dianthus Therapeutics, Inc.'s principal executive offices located?
The company's business address is 7 Times Square, 43rd Floor, New York, NY 10036.
What is the fiscal year end for Dianthus Therapeutics, Inc.?
The fiscal year end for Dianthus Therapeutics, Inc. is December 31.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 12, 2025 regarding Dianthus Therapeutics, Inc. /DE/ (DNTH).